Drugs / YY003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06481475 | Jan → Oct 2025 | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YY003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481475 ↗ |
| Known as | Botulinum Neurotoxin Type A | “A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for...” NCT06481475 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Botulinum Neurotoxin Type A Injection (YY003)” NCT06481475 ↗ |
| Route | Intramuscular | “Single treatment, intramuscularly injected into five sites” NCT06481475 ↗ |